2014 San Antonio Breast Cancer Symposium

Am literally waiting for SOFT trial results with baited breath. Had partial first dose of CMF on Friday and had allergic reaction to 5FU. (Never got the cyclophosphamide) Last night had acute pelvic pain and was in urgent care with what looks like ruptured ovarian cyst--I see there are 4 reported cases to the FDA following Methotrexate. I have oncotype of 20 and was ambivalent at best towards chemo as it looks like 95% or greater chance that it would not change anything about my outcome. Now with rare allergy and possibly incredibly rare side effect, I feel my body is saying NO NO NO. Have second opinion with another MO on Thursday and she agreed that San Antonio is incredibly timely for me.

Yes, thank you for posting this info! I'm waiting for the results of the SOFT trial tomorrow. I'm hoping it will give me some clear guidance.

I thought SOFT was out today ?

http://medicalxpress.com/news/2014-12-male-breast-...

"Male breast cancer is different"

"One important difference is in the rates of survival. The study found that while survival for men with breast cancer has improved, it hasn't kept pace with the strides made in treating breast cancer in women."

"Although we saw a significant improvement in overall survival for male breast cancer patientsover time, the prognosis for men with breast cancer has not been improving as much as for women with the disease," Dr. Fatima Cardoso, director of the breast unit at the Champalimaud Cancer Center in Lisbon, Portugal, said in a news release from the American Association for Cancer Research.

"This is largely because male breast cancer is a rare disease—it accounts for just 1 percent of breast cancers—and we know very little about its biology and how best to treat patients," Cardoso said....................

..............."Cardoso is due to present the findings Dec. 9 at the 2014 San Antonio Breast Cancer Symposium. The symposium is a partnership of the University of Texas Health Science Center, the American Association for Cancer Research and Baylor College of Medicine."........

So it sounds like there is a benefit specifically for those who have had chemo and remained premenopausal? And an even bigger benefit, in that same subgroup, with an AI plus ovarian suppression vs. tamoxifen and ovarian suppression. Am I understanding it correctly? Was there any analysis done specific to those premenopausal early stagers that did NOT get chemo? Thanks for your insights!

Isn't the TAILOR (I think that's what it's called) trial results also supposed to be released? That specifically was for premenopausal women who didn't have chemo I believe.

I'm anxiously awaiting the full report from the SOFT trial myself. Thanks VR for keeping us updated!

Sounds to me like the addition of ovarian suppression really did not make a statistically significant difference in patients who already had favorable enough prognostic features as to not warrant chemotherapy. The benefit was seen in the younger women who had prognostic features that warranted chemotherapy, and who were presumably young enough that they were still premenopausal after chemotherapy. That's where it had benefit. And in those women, the benefit was greatest with AI and OS.

I'm waiting for a more nuanced interpretation.

Sorrento Therapeutics (Ticker: SRNE) is trending up over 10% in the market today.
They are working on MYC inhibitor, KJ-Pyr-9, a Tumor Stopping Molecule. No clue what any of that is, but they must have reported some good news at the conference.

Just had a minute to look for Sorrento Therapeutics. Cannot vouch for any accuracy but does mention SA Breast Conference. Found others from biz sites but this is from company itself.